Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 7CNS 7Genitourinary 1

Conditions

Prostatic Neoplasms 7Urinary Bladder Neoplasms 4Carcinoma, Renal Cell 4Kidney Neoplasms 3Urethral Neoplasms 1Non-Metastatic Prostate Cancer 1Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter 1Locally Advanced Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

cediranib 1carboxyamido-triazole 1capmatinib 1Thalidomide 1Paclitaxel 1Gefitinib 1Fluorodeoxyglucose F18 1Fentanyl 1FPP(RGD)2 1Everolimus 1Erlotinib Hydrochloride 1Docetaxel 1CLR1404 1Bevacizumab 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Gefitinib × Genitourinary × Clear all
NCT00085566 2016-01-20

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
61 enrolled 8 charts
CNSGenitourinarySarcoma

Brain Neoplasms, Glioblastoma, Prostatic Neoplasms, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡